NASDAQ: NGNERUSSELL2000
Neurogene Inc.
Healthcare · Biotechnology · Headquartered in New York City, US
Price
Loading chart…
Overview
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
History & business model
This section is waiting to be written.
InvestWiki is community-edited. Contribute a plain-English history of Neurogene Inc., its business model, key products, and controversies.